How GLP-1 Medications Work: A Plain-English Guide

If you're considering Ozempic, Wegovy, Mounjaro, or a similar medication — or you've already started one — you've probably realised the pharmacist's leaflet doesn't actually explain how the thing works. It just tells you what to expect and when to call a doctor. So let's fix that, using the actual clinical research rather than forum guesswork.

It starts with a hormone your gut already makes

GLP-1 (glucagon-like peptide-1) is a naturally occurring hormone, secreted mainly by L-cells in your intestines whenever you eat (Kalra et al., 2022). It's part of a feedback loop called the "incretin effect": on nutrient intake, GLP-1 enhances glucose-dependent insulin secretion, suppresses glucagon, and slows gastric emptying (Kalra et al., 2022; Kommu & Whitfield, 2024).

The catch is that natural GLP-1 barely lasts — it's broken down by the enzyme DPP-4 within two to three minutes (Latif et al., 2025). GLP-1 receptor agonist medications, such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), are built to resist that breakdown, extending the same signal from minutes to roughly a week (Latif et al., 2025).

Three mechanisms, one hormone signal

Slower gastric emptying. GLP-1 reduces gastric muscle contractions and can activate the vagus nerve, both of which extend how long food stays in the stomach — directly increasing the feeling of fullness after a meal (Zhao et al., 2024).

Appetite regulation in the brain. Evidence increasingly points to GLP-1 receptor agonists acting directly on hypothalamic neurons to reduce appetite and energy intake, rather than this simply being a downstream effect of slower digestion (Jalleh et al., 2024). This central mechanism also involves modulating other appetite-related hormones, including ghrelin, leptin, and peptide YY (Ard & Fitch, 2025).

Improved blood sugar regulation. Because insulin release only increases when glucose is already elevated, and glucagon is appropriately suppressed, these medications carry comparatively low hypoglycaemia risk on their own (Kommu & Whitfield, 2024).

Tirzepatide adds a second hormone target, GIP, on top of GLP-1 — part of why dual-action medications tend to produce larger average weight loss in trials, though individual response still varies considerably.

Why this explains what you're actually feeling

Why nausea is worst early on. It's a direct consequence of slower gastric emptying, not a side effect unrelated to how the drug works (Zhao et al., 2024) — which is also why it typically settles as the digestive system adapts.

Why muscle loss is a real and measurable risk. Trial data from Regeneron's COURAGE programme found that roughly a third of semaglutide-induced weight loss came from lean mass rather than fat (Regeneron, 2025). A separate one-year study (SEMALEAN) found lean mass losses stabilised over time and grip strength actually improved by month 12 — but the initial lean-mass drop in the first months was real and measurable (SEMALEAN study, 2025). Without deliberate protein intake and resistance training, a meaningful share of what comes off can be muscle, not fat.

Why appetite often returns after stopping. The medication suppresses hunger signals while active in the body — it doesn't permanently reset appetite regulation. In the STEP 4 trial, participants who switched from semaglutide to placebo regained an average of 6.9% of body weight over the following 48 weeks, while those who stayed on treatment continued losing weight (cited in Wilding et al., cf. Sarma & Palanivelu, 2025). A separate trial of a muscle-preserving compound found the placebo group regained 43% of their previously lost weight within just 12 weeks of stopping semaglutide (Veru Inc., 2025) — a striking illustration of how quickly rebound can happen without a maintenance plan.

The part the injection alone doesn't cover

A GLP-1 medication changes your biology. It doesn't build you a nutrition plan, a strength routine, or a maintenance strategy for when you eventually come off it — and the research above shows exactly why those gaps matter: measurable muscle loss during treatment, and measurable rebound after stopping, are the norm rather than the exception without additional support.

This is exactly the gap our While You're On It programme is built around — structured nutrition and training support for the months you're actively on your medication, so the weight you lose comes from fat rather than muscle.

And because rebound weight gain is common enough to show up clearly in clinical trial data, we built a separate Coming Off It programme specifically for the tapering and maintenance phase, so you're not left figuring that part out alone.

If you want extra nutritional support alongside either programme, our Alongside Daily Support powder is formulated to help hit protein and micronutrient targets when appetite is low — one of the most common gaps we see in people on GLP-1s.

And if you'd rather have a real person guiding your specific situation than piece it together from forum threads, our 1:1 coaching covers exactly that, from dose changes through to long-term maintenance.

The bottom line

GLP-1 medications work by amplifying a hormone your body already produces, extending its effect from minutes to a week, and using that extended signal to slow digestion, quiet appetite, and improve blood sugar control. The clinical evidence is genuinely robust — but it also shows, clearly, that the medication is one input into a bigger picture that includes what you eat, how you train, and what your plan is for when treatment ends.

This article is for general information and isn't a substitute for medical advice. Always discuss starting, adjusting, or stopping a GLP-1 medication with your prescriber.

References

Ard, J., & Fitch, A. (2025). Mechanisms of GLP-1 receptor agonist-induced weight loss: A review of central and peripheral pathways in appetite and energy regulation. The American Journal of Medicine. https://www.amjmed.com/article/S0002-9343(25)00059-2/fulltext

Jalleh, R. J., et al. (2024). Clinical consequences of delayed gastric emptying with GLP-1 receptor agonists and tirzepatide. The Journal of Clinical Endocrinology & Metabolism, 110(1), 1–15. https://academic.oup.com/jcem/article/110/1/1/7824836

Kalra, S., et al. (2022). GLP-1 receptor agonist as a modulator of innate immunity. Frontiers in Immunology. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9772276/

Kommu, S., & Whitfield, P. (2024). Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Signal Transduction and Targeted Therapy. https://www.nature.com/articles/s41392-024-01931-z

Latif, W., et al. (2025). Glucagonlike peptide-1 receptor agonists: The good, the bad, and the ugly — benefits for glucose control and weight loss with side effects of delaying gastric emptying. Journal of Nuclear Medicine Technology, 52(1), 3. https://tech.snmjournals.org/content/52/1/3

Regeneron Pharmaceuticals. (2025, June 2). Interim results from ongoing Phase 2 COURAGE trial confirm potential to improve the quality of semaglutide-induced weight loss by preserving lean mass [Press release]. https://www.globenewswire.com

Sarma, S., & Palanivelu, C. (2025). Rebound or retention: A meta-analysis of weight regain after the discontinuation of GLP-1 receptor agonists and other anti-obesity drugs. PMC. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12535773/

SEMALEAN study. (2025). Impact of semaglutide on fat mass, lean mass and muscle function in patients with obesity. PMC. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12673431/

Veru Inc. (2025, June 24). Veru reports positive results from Phase 2b QUALITY and maintenance extension study showing enobosarm significantly reduced body weight regain, prevented fat regain, and preserved lean mass after semaglutide discontinuation [Press release]. https://ir.verupharma.com

Zhao, X., et al. (2024). Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Signal Transduction and Targeted Therapy. https://www.nature.com/articles/s41392-024-01931-z